HC Wainwright lifts PT on Neurocrine after Soleno deal

Neurocrine Biosciences

07/04/2026 12:09

** Brokerage HC Wainwright reiterates U.S. drugmaker Neurocrine Biosciences NBIX.O at “buy”, raises PT to $215 from $192 after its deal to acquire Soleno Therapeutics SLNO.O

** Brokerage says the acquisition adds VYKAT XR, a newly approved treatment for extreme, uncontrollable hunger linked to a rare genetic condition, creating a second commercial growth engine

** Brokerage adds Neurocrine’s endocrinology salesforce and payer reach could accelerate uptake beyond Soleno’s standalone trajectory

** Brokerage expects the deal to diversify revenue away from Neurocrine’s movement‑disorder drug Ingrezza as competition and patent risks increase over the longer term

** Brokerage models VYKAT XR sales of $193 mln in 2026, ramping to more than $1 bln by 2031

** As of last close, NBIX stock down 7% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))